Loading clinical trials...
Loading clinical trials...
Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation
Conditions
Interventions
Peg interferon alfa-2b
Locations
1
China
Shanghai Jiao Tong University Affilated First People's Hospital
Shanghai, Shanghai Municipality, China
Start Date
August 1, 2015
Primary Completion Date
December 1, 2021
Completion Date
December 1, 2021
Last Updated
March 16, 2023
NCT06237452
NCT05739825
NCT05467891
NCT05557474
NCT07263438
NCT07341815
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions